NCT04082442View on ClinicalTrials.gov

Evolocumab in Patients With Acute MI

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

October 25, 2024

Study Completion Date

October 25, 2024

Conditions

Acute Coronary Syndrome

Interventions

DRUG

Evolocumab

420 mg evolocumab.

DRUG

Placebos

Matching placebo.

Trial Locations (1)

21287

The Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

Johns Hopkins University

OTHER